Demant A/S/DKr DEMANT
1D1W1MYTD1Y5YMAX
Capital at risk
About Demant A/S
Demant A/S is a Danish company that operates in the healthcare industry, primarily focusing on hearing health. The company designs, develops, and manufactures hearing aids, audiometric equipment, and personal communication devices. Established in 1904, Demant has grown to become a globally recognized player in the hearing healthcare sector. Headquartered in Smørum, Denmark, Demant's products and services are available worldwide through a network of subsidiaries and distributors. The company is noted for integrating advanced technology into its offerings, allowing for improved user experiences and health outcomes. Its strategic position is strengthened by a continuous focus on innovation and a comprehensive product portfolio that caters to various aspects of hearing health.
- Ticker
- DKr DEMANT
- Sector
- Health
- Primary listing
- CSE
- Employees
- 26,616
- Headquarters
- Smørum, Denmark
- Website
- www.demant.com
Demant A/S Metrics
BasicAdvanced
kr 61B
37.93
kr 7.64
0.76
-
Price and volume
Market cap
kr 61B
Beta
0.76
52-week high
kr 299.00
52-week low
kr 175.00
Average daily volume
318K
Financial strength
Current ratio
0.821
Quick ratio
0.531
Long term debt to equity
115.985
Total debt to equity
179.217
Interest coverage (TTM)
7.82%
Profitability
EBITDA (TTM)
4,972
Gross margin (TTM)
76.25%
Net profit margin (TTM)
6.55%
Operating margin (TTM)
17.20%
Effective tax rate (TTM)
23.76%
Revenue per employee (TTM)
kr 930,000
Management effectiveness
Return on assets (TTM)
7.29%
Return on equity (TTM)
23.30%
Valuation
Price to earnings (TTM)
37.926
Price to revenue (TTM)
2.483
Price to book
5.44
Price to tangible book (TTM)
-6.48
Price to free cash flow (TTM)
19.704
Free cash flow yield (TTM)
5.08%
Free cash flow per share (TTM)
14.707
Growth
Revenue change (TTM)
9.06%
Earnings per share change (TTM)
-29.26%
3-year revenue growth (CAGR)
5.62%
10-year revenue growth (CAGR)
7.98%
3-year earnings per share growth (CAGR)
1.92%
10-year earnings per share growth (CAGR)
3.98%
Bulls say / Bears say
Demant reported group organic revenue growth of 6% in Q1 2026, driven by strong performance in its Hearing Aids business, reflecting robust demand and effective product rollouts (MarketScreener)
In Q2 2026, Demant achieved 9% organic sales growth and simultaneously upgraded its full‐year organic growth guidance to 6–7%, demonstrating strong operating momentum and management confidence (MarketScreener)
Management’s 2026 outlook projects EBIT before special items of DKK 4.1–4.5 billion, underscoring a commitment to margin expansion and solid profitability benchmarks (MarketScreener)
Amplifon’s planned acquisition of GN Store Nord’s hearing‐aid unit is expected to intensify competitive pressure on Demant amid sluggish sector demand, potentially denting its market share (Bloomberg)
Demant shares fell as much as 3.3% after Bank of America lowered its price target to the weakest among analysts, signaling reduced investor confidence in the stock’s near‐term performance (MarketScreener)
Global hearing‐aid unit shipments grew by only around 3% in the first half of 2026, according to industry estimates, indicating limited market expansion and potential headwinds for Demant’s organic growth ambitions (FinancialFilings)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
Funds containing Demant A/S
AllEURGBPUSD
Fund name | Fund size | DKr DEMANT weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €704M | 0.21% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 0.19% |
iShares MSCI Europe Health Care Sector£ESIH | £742M | 0.19% |
iShares MSCI Europe ex-UK€IEUX | €1.5B | 0.04% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.